RANKL-IN-1 is a selective inhibitor of receptor activator of nuclear factor-κB ligand (RANKL), with a KD value of 7.6 μM. It shows inhibitory activity and selectivity in osteoclastogenesis, with an IC50 of 0.07 μM and a selectivity index (SI) of 82.57. By directly binding to RANKL, RANKL-IN-1 blocks the activation of RANKL-induced NF-κB and MAPK pathways. This compound is applicable in research on metabolic diseases such as osteoporosis.

RANKL-IN-1 (Compound 19u) administered at concentrations of 50-400 nM over 4 days exhibits no significant cytotoxicity in RAW264.7 cells. It effectively inhibits RANKL-induced osteoclastogenesis without affecting osteoblast differentiation in these cells. Additionally, RANKL-IN-1 reduces RANKL-induced reactive oxygen species (ROS) levels and suppresses bone resorption in RAW264.7 cells. The compound also inhibits the expression of proteins associated with RANKL-induced osteoclast differentiation in RAW264.7 cells.

RANKL-IN-1 (Compound 19u) at concentrations of 0.313-1.25 μg/mL over 96 hours was found to reduce bone loss in a zebrafish osteoporosis model. Additionally, RANKL-IN-1 administered orally at 0.5-2 mg/kg every two days for 11 weeks prevented systemic bone loss in a mouse model of ovariectomy-induced osteoporosis.